Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

Clinical trial NCT03785249 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT03785249
Sponsor: Mirati Therapeutics Inc.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Advanced Cancer Metastatic Cancer Malignant Neoplastic Disease

Start date: 2019-01-15
Primary completion: 2026-06-23
Enrollment: 731

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.